MMP9 peptide (Carboxyterminal end) (ab41067)
Constituents: 0.001% Tween 20, 30mM HEPES, 2mM EDTA, 150mM Sodium chloride, pH 6.75
Our Abpromise guarantee covers the use of ab41067 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
- 82 kDa matrix metalloproteinase-992 kDa gelatinase92 kDa type IV collagenase
- CLG 4BCLG 4BCLG4BCollagenase Type 4 betaCollagenase Type 4 betaCollagenase type IV 92 KDCollagenase type IV 92 KDEC 18.104.22.168Gelatinase 92 KDGelatinase 92 KDGelatinase BGelatinase betaGelatinase betaGelatinaseBGELBGELBMacrophage gelatinaseMacrophage gelatinaseMANDP2Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)Matrix Metalloproteinase 9Matrix Metalloproteinase 9MMP 9MMP-9MMP9MMP9_HUMANType V collagenaseType V collagenase
-Leu bond. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide.
Metaphyseal anadysplasia 2 (MANDP2) [MIM:613073]: A bone development disorder characterized by skeletal anomalies that resolve spontaneously with age. Clinical characteristics are evident from the first months of life and include slight shortness of stature and a mild varus deformity of the legs. Patients attain a normal stature in adolescence and show improvement or complete resolution of varus deformity of the legs and rhizomelic micromelia. Note=The disease is caused by mutations affecting the gene represented in this entry.
Contains 3 fibronectin type-II domains.
Contains 4 hemopexin-like domains.
modificationsProcessing of the precursor yields different active forms of 64, 67 and 82 kDa. Sequentially processing by MMP3 yields the 82 kDa matrix metalloproteinase-9.
N- and O-glycosylated.
References for MMP9 peptide (Carboxyterminal end) (ab41067)
ab41067 has not yet been referenced specifically in any publications.